<DOC>
	<DOCNO>NCT01943721</DOCNO>
	<brief_summary>The objective Phase 1 study evaluate VISION5 Product 's safety efficacy .</brief_summary>
	<brief_title>A Study VISION5 Product Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Written inform consent Primary openangle glaucoma ocular hypertension eye Bestcorrected distance vision 20/100 well Stable visual field Cuptodisc ratio great 0.8 Laser surgery glaucoma/ocular hypertension one eye within last 12 month Corneal refractive surgery within prior 6 month Past history incisional surgery glaucoma time Corneal abnormality would interfere tonometry reading Current participation investigational drug device study participation study within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>